Synthetic biologists.
Immunologists.
Data scientists.

Together, we’re making selective mRNA drugs to cure serious illnesses.

Our goal is to improve patient experience by delivering medicines that will challenge the standard of care and prolong life.

Leadership Team

Yusuf Erkul

Yusuf Erkul MD, MBA

Chief Executive Officer & Cofounder

Physician entrepreneur who developed an FDA-approved cancer drug at Merck & Co
Burak Yilmaz

Burak Yilmaz MS

President & Cofounder

Has 24 patents and 15 years of RNA/DNA experience
Manfred Kraus

Manfred Kraus PhD

SVP, Head of R&D Therapeutics
Firat Ileri

Firat Ileri

Board Member
Joseph Parrella

Joseph Parrella

VP of CMC
Pablo Lubroth

Pablo Lubroth MPhil

Board Observer
Gladys Nunez

Gladys Nunez

Board Observer
Craig Gibbs

Craig Gibbs

Business Advisor
Stephen DiPalma

Stephen DiPalma MBA

Chief Financial Officer
Balkrishen Bhat

Balkrishen Bhat PhD

Int. Head of LNP Formulation
Jeff Ozdemir

Jeff Ozdemir PhD

Head of Platform & Cofounder

Advisory
Board

Edward Benz Jr

Edward Benz Jr MD

Clinical Advisor, Medical Oncology

President & CEO Emeritus of Dana Farber Cancer Institute, Harvard Medical School
Oliver Rosen

Oliver Rosen MD

Clinical advisor

CMO of Akamis Bio
Peter <br>Blume-Jensen

Peter
Blume-Jensen MD, PhD

Clinical Advisor, Cancer Drug Development

CEO of Acrivon Therapeutics and former Head of Oncology at of Merck
Umut Eser

Umut Eser PhD

Machine Learning Advisor

CTO & Co-Founder of Weave
Nikolai Slavov

Nikolai Slavov PhD

Scientfic Advisor, mRNA Translation

Founding Director of Parallel Squared Technology Institute & Professor at Northeastern University
Dean <br>Felsher

Dean
Felsher MD, PhD

Clinical Advisor, Translational Oncology

Director of Stanford Medicine Translational Research & Applied Medicine at Stanford Medical School
Dan Peer

Dan Peer PhD

Scientific Advisor

Vice President for R&D, Tel Aviv University

This
could
be you.

Careers